Ask AI
DESTINY Gastric04
DESTINY-Gastric04: T-DXd vs Ramucirumab + Paclitaxel as Second-line Therapy in HER2+ Unresectable/Metastatic Gastric Cancer/GEJ Adenocarcinoma

Released: June 05, 2025

Expiration: December 04, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 05, 2025

Expiration: December 04, 2025